Malignant Neoplasm Clinical Trial
Official title:
Does Increased Mobility Assessed With 3D Motion Tracking Technology Lead to Early Post-Operative Recovery Among Patients Undergoing Oncologic Surgeries
Verified date | July 2022 |
Source | Roswell Park Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies the impact of early mobility tracked with a 3-dimensional (3D) motion tracking technology (XSENS) on post-surgery recovery in patients undergoing oncologic surgeries. Xsens uses wireless measurements which could be used in clinical settings to objectively measure movement patterns (the joint range of movement and the distance of movement) during functional activities. Post-surgery mobility tracking may help doctors to identify the minimum required level of mobility after inpatient oncologic surgeries to enhance early post-surgery recovery and decrease early post-surgery complications.
Status | Terminated |
Enrollment | 17 |
Est. completion date | April 10, 2020 |
Est. primary completion date | April 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Ambulant inpatient with a stay of >= 2 days after any inpatient oncologic surgery - Eastern Cooperative Oncology Group (ECOG) scale of performance status of less than 3 - American Society of Anesthesiologist score (ASA) 3 or less - Participants who do not engage in regular exercise regimen before the surgery (other than regular occupational physical therapy) - Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: - Patients with altered mental status - Patients with psychiatric illness - ECOG scale performance status 3 or more - ASA score of 4 - Participants who engage in regular exercise regimen before surgery (at least one session per week) - Patients with restricted movement due to other diseases - Patients who require continuous monitoring |
Country | Name | City | State |
---|---|---|---|
United States | Roswell Park Cancer Institute | Buffalo | New York |
Lead Sponsor | Collaborator |
---|---|
Roswell Park Cancer Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in Mobility | changes in mobility (as measured by average velocity of pelvis) from baseline to discharge are compared between groups using a one-sided, two-sample t-test. | Baseline up to 30 days post discharge | |
Primary | Early Return of Bowel Motion | Days from operation to passing flatus and/or stool, treated as continuous measure | Up to 30 days after discharge | |
Primary | Presence or Absence of Nausea and/or Vomiting | Presence or absence of nausea and/or vomiting, treated as a binary variable | Up to 30 days after discharge | |
Primary | Presence or Absence of Chest Symptoms | Presence or absence of chest symptoms (cough, sputum, and ability of using incentive spirometry), treated as a binary variable | Up to 30 days after discharge | |
Primary | Early Discharge From the Hospital | Days from operation until hospital discharge, treated as continuous variable | Up to 30 days after discharge | |
Primary | Surgical Related Complications and Readmissions | Presence or absence of surgical complication (including readmission), treated as a binary variable | Up to 30 days after discharge | |
Secondary | Range of Joint Movement in Upper and Lower Joints of Body | Will be measured using the 3 dimensional (3D) motion tracking system (Xsens), to identify the minimum required level of mobility for better early postoperative course recovery. | Up to 30 days after discharge | |
Secondary | Post-surgical Complications | The complication status (present/absent) and grades will be summarized by group and compared using Fisher's exact test or the chi-square test, as appropriate. | Up to 30 days post discharge | |
Secondary | Change in Exercise Habits Outside of the Hospital | Post study questionnaire . | Up to 3 months post discharge | |
Secondary | Application of Sensors in a Hospital Setting | Adequate application of sensors, treated as a categorical variable | Up to 3 months post discharge | |
Secondary | Mobility Quality of Life Questionnaire | The correlation between complication status and changes in mobility may be evaluated using a post study questionnaire. | Up to 3 months post discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02243592 -
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
|
||
Completed |
NCT03445572 -
Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer
|
N/A | |
Active, not recruiting |
NCT02860039 -
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT01635413 -
Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)
|
N/A | |
Completed |
NCT00026169 -
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
|
Phase 1 | |
Recruiting |
NCT04534075 -
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
|
Phase 3 | |
Active, not recruiting |
NCT01806129 -
Reproductive Health Program in Patients With Cancer
|
N/A | |
Recruiting |
NCT03915717 -
Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
|
||
Recruiting |
NCT02280161 -
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
|
||
Recruiting |
NCT05520281 -
Short-term Psychodynamic Psychotherapy in Serious Physical Illness
|
N/A | |
Terminated |
NCT00532064 -
Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
|
||
Completed |
NCT04990882 -
FAPI PET/CT Prospective Interobserver Agreement
|
||
Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05886764 -
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
|
N/A | |
Completed |
NCT01506440 -
Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy
|
||
Completed |
NCT01432431 -
Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff
|
N/A |